BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 1848473)

  • 1. Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features.
    Toner GC; Geller NL; Lin SY; Bosl GJ
    Cancer; 1991 Apr; 67(8):2049-57. PubMed ID: 1848473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party.
    Mead GM; Stenning SP; Parkinson MC; Horwich A; Fossa SD; Wilkinson PM; Kaye SB; Newlands ES; Cook PA
    J Clin Oncol; 1992 Jan; 10(1):85-94. PubMed ID: 1309383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival after resection for metastatic testicular nonseminomatous germ cell cancer to the lung or mediastinum.
    Kesler KA; Kruter LE; Perkins SM; Rieger KM; Sullivan KJ; Runyan ML; Brown JW; Einhorn LH
    Ann Thorac Surg; 2011 Apr; 91(4):1085-93; discussion 1093. PubMed ID: 21440128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum-based chemotherapy of primary extragonadal germ cell tumours: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Aravantinos G; Visvikis A; Bakoyiannis C; Halikia A; Kalofonos C; Kosmidis P; Skarlos D; Fountzilas G
    Oncology; 1999 Jul; 57(1):1-9. PubMed ID: 10394118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extragonadal germ cell tumors: prognostic factors and long-term follow-up.
    Aparicio J; Montalar J; Munárriz EB; Reynés G; Gómez-Codina J; Pastor M; Herranz C
    Eur Urol; 1995; 28(1):19-24. PubMed ID: 8521889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival and prognostic factors associated with metastatic nonseminomatous testicular and extragonadal germ cell tumors.
    Kawakita M; Terachi T; Hida S; Takeuchi H; Yoshida O
    Int J Urol; 1994 Jun; 1(2):172-6. PubMed ID: 7627853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors.
    Funt SA; Patil S; Feldman DR; Motzer RJ; Bajorin DF; Sheinfeld J; Tickoo SK; Reuter VE; Bosl GJ
    J Clin Oncol; 2019 Sep; 37(26):2329-2337. PubMed ID: 31233353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience.
    De Giorgi U; Demirer T; Wandt H; Taverna C; Siegert W; Bornhauser M; Kozak T; Papiani G; Ballardini M; Rosti G;
    Ann Oncol; 2005 Jan; 16(1):146-51. PubMed ID: 15598952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling.
    Kollmannsberger C; Nichols C; Meisner C; Mayer F; Kanz L; Bokemeyer C
    Ann Oncol; 2000 Sep; 11(9):1115-20. PubMed ID: 11061604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
    Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic concordance of resected metastatic nonseminomatous germ cell tumors in the chest.
    Donahoe LL; Nason GJ; Bedard PL; Hansen AR; Jewett MAS; Hamilton RJ; de Perrot M
    J Thorac Cardiovasc Surg; 2021 Mar; 161(3):856-868.e1. PubMed ID: 33478834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study.
    Fizazi K; Oldenburg J; Dunant A; Chen I; Salvioni R; Hartmann JT; De Santis M; Daugaard G; Flechon A; de Giorgi U; Tjulandin S; Schmoll HJ; Bouzy J; Fossa SD; Fromont G
    Ann Oncol; 2008 Feb; 19(2):259-64. PubMed ID: 18042838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive chemotherapy in poor-prognosis nonseminomatous germ cell tumors of the testis.
    Germá Lluch JR; Seguí Palmer MA; Climent Durán MA; Blanco Guerrero R; Fernández Sagarra A; Villavicencio H; Solé Balcells FJ
    Eur Urol; 1992; 21(4):287-93. PubMed ID: 1333957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of tumor site and histology on long-term survival in 193 children with extracranial germ cell tumors.
    De Backer A; Madern GC; Pieters R; Haentjens P; Hakvoort-Cammel FG; Oosterhuis JW; Hazebroek FW
    Eur J Pediatr Surg; 2008 Feb; 18(1):1-6. PubMed ID: 18302061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary mediastinal nonseminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy.
    Fizazi K; Culine S; Droz JP; Kramar A; Théodore C; Ruffié P; Le Chevalier T
    J Clin Oncol; 1998 Feb; 16(2):725-32. PubMed ID: 9469363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mediastinal metastases from testicular nonseminomatous germ cell tumors: patterns of dissemination and predictors of long-term survival with surgery.
    Kesler KA; Brooks JA; Rieger KM; Fineberg NS; Einhorn LH; Brown JW
    J Thorac Cardiovasc Surg; 2003 Apr; 125(4):913-23. PubMed ID: 12698156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection.
    Toner GC; Panicek DM; Heelan RT; Geller NL; Lin SY; Bajorin D; Motzer RJ; Scher HI; Herr HW; Morse MJ
    J Clin Oncol; 1990 Oct; 8(10):1683-94. PubMed ID: 2170590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site.
    Masterson TA; Carver BS; Shayegan B; Feldman DR; Motzer RJ; Bosl GJ; Sheinfeld J
    Urology; 2012 May; 79(5):1079-84. PubMed ID: 22446341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group.
    Fizazi K; Tjulandin S; Salvioni R; Germà-Lluch JR; Bouzy J; Ragan D; Bokemeyer C; Gerl A; Fléchon A; de Bono JS; Stenning S; Horwich A; Pont J; Albers P; De Giorgi U; Bower M; Bulanov A; Pizzocaro G; Aparicio J; Nichols CR; Théodore C; Hartmann JT; Schmoll HJ; Kaye SB; Culine S; Droz JP; Mahé C
    J Clin Oncol; 2001 May; 19(10):2647-57. PubMed ID: 11352956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
    Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
    Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.